PhRMA Embraces Teva Across Brand-Generic Divide
Executive Summary
PhRMA accepts Teva's request for membership; BIO rejected Teva five years ago.
You may also be interested in...
Teva, Allergan Probably Won't Need More Divestments To Get FTC Approval
Parties have already agreed to sell more than 50 products so far, but are still extending outside date for closing of Teva's acquisition of Allergan's generic business until October.
For Generics Industry, Will Larger Firms Mean Weaker Lobbying?
New CEO Chip Davis wants GPhA sitting at the table in policy debates rather than being on the menu, but industry consolidation means there are fewer dues-paying members to fill the chairs.
Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming
Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.